EpCAM and α-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma

Cancer Research

Volumn 68, Issue 5, 2008, Pages 1451-1461

  Yamashita, Taro ^a   Forgues, Marshonna ^a   Wang, Wei ^a,c   Jin, Woo Kim ^a,d   Ye, Qinghai ^b   Jia, Huliang ^b   Budhu, Anuradha ^a   Zanetti, Krista A ^a   Chen, Yidong ^a   Qin, Lun Xiu ^b   Tang, Zhao You ^b   Xin, Wei Wang ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FUDAN UNIVERSITY   (China)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d WAKE FOREST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BETA CATENIN; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; CYTOKERATIN 19; EPITHELIAL CELL ADHESION MOLECULE; PROTEIN P53; STEM CELL FACTOR; WNT PROTEIN;

ARTICLE; CANCER PATIENT; CELL LINEAGE; CELL MATURATION; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL; VALIDATION PROCESS;

ALPHA-FETOPROTEINS; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL LINEAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MODELS, GENETIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 40449099255     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6013     Document Type: Article

References (50)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
4. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermalgrowth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
6. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-56.
7. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
8. Sala M, Forner A, Varela M, Bruix J. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis 2005;25:171-80.
9. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-23.
10. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-76.
11. Ding SJ, Li Y, Tan YX, et al. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 2004;3:73-81.
12. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111.
13. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-6.
14. Wurmbach E, Chen YB, Khitrov G, et al. Genomewide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007;45:938-47.
15. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003;361:923-9.
16. Kim JW, Ye Q, Forgues M, et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 2004;39:518-27.
17. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A 1979;76:1438-42.
18. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77:699-712.
19. Winter MJ, Nagelkerken B, Mertens AE, Rees-Bakker HA, Briaire-de Bruijn IH, Litvinov SV. Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak. Exp Cell Res 2003;285:50-8.
20. de Boer CJ, van Krieken JH, Janssen-van Rhijn CM, Litvinov SV. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 1999;188:201-6.
21. Schmelzer E, Wauthier E, Reid LM. The phenotypes of pluripotent human hepatic progenitors. Stem Cells 2006;24:1852-8.
22. Ruck P, Wichert G, Handgretinger R, Kaiserling E. Ep-CAM in malignant liver tumours. J Pathol 2000;191:102-3.
23. Takayasu K, Arii S, Ikai I et al. Prospective cohort study of transarterialchem oembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-9.
24. Taketa K. α-Fetoprotein: reevaluation in hepatology. Hepatology 1990;12:1420-32.
25. Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatialcontrol of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol 2005;7:823-30.
26. Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, Varmus HE. FGF-20 and DKK1 are transcriptionaltargets of β-catenin and FGF-20 is implicated in cancer and development. EMBO J 2005;24:73-84.
27. Sekiya T, Adachi S, Kohu K et al. Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factor-β signaling, as a target of the β-catenin pathway in colorectal tumor cells. J Biol Chem 2004;279:6840-6.
28. Schmelzer E, Zhang L, Bruce A, et al. Human hepatic stem cells from fetal and postnatal donors. J Exp Med 2007;204:1973-87.
29. Johnson Pj. The role of serum α-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001;5:145-59.
30. Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology 2004;39:1477-87.
31. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
32. Thorgeirsson SS, Grisham JW. Hepatic stem cells. Semin Liver Dis 2003;23:301.
33. Libbrecht L, Desmet V, Van Damme B, Roskams T. The immunohistochemicalphenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J Hepatol 2000;33:76-84.
34. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006;25:3818-22.
35. Dan YY, Riehle KJ, Lazaro C, et al. Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci U S A 2006;103:9912-7.
36. Yovchev MI, Grozdanov PN, Joseph B, Gupta S, Dabeva MD. Novelhepatic progenitor cell surface markers in the adult rat liver. Hepatology 2007;45:139-49.
37. Robrechts C, De Vos R, Van den HM, et al. Primary liver tumour of intermediate (hepatocyte-bile duct cell) phenotype: a progenitor cell tumour? Liver 1998;18:288-93.
38. Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006;441:1068-74.
39. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50.
40. Micsenyi A, Tan X, Sneddon T, Luo JH, Michalopoulos GK, Monga SP. β-Catenin is temporally regulated during normal liver development. Gastroenterology 2004;126:1134-46.
41. Monga SP, Monga HK, Tan X, Mule K, Pediaditakis P, Michalopoulos GK. β-Catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 2003;124:202-16.
42. Branda M, Wands JR. Signaltransduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 2006;43:891-902.
43. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003;1653:1-24.
44. Merle P, de la MS, Kim M, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 2004;127:1110-22.
45. Inagawa S, Itabashi M, Adachi S, et al. Expression and prognostic roles of β-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 2002;8:450-6.
46. Mao TL, Chu JS, Jeng YM, Lai PL, Hsu HC. Expression of mutant nuclear β-catenin correlates with noninvasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol2001;193:95-101.
47. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. β-Catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157:763-70.
48. Endo K, Ueda T, Ueyama J, Ohta T, Terada T. Immunoreactive E-cadherin, α-catenin, β-catenin, and γ-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol 2000;31:558-65.
49. Wong CM, Fan ST, Ng IO. β-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001;92:136-45.
50. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-β-catenin signaling in hepatocellular carcinoma. Cancer Res 2007;67:10831-9.